Summit Therapeutics Inc. — Director's Dealing 2020

Oct 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2020-10-02

Reporting Person: DUGGAN ROBERT W (Director, Chief Executive Officer, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-02	Common Stock	$3.34	A	9730539	Acquired		Common Stock (9730539)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	42224677	Direct

Footnotes

F1: Represents the minimum number of shares that the Reporting Person shall be obligated to purchase in a private placement pursuant to a Securities Purchase Agreement, dated October 2, 2020, by and between the Reporting Person and the Issuer (the "Purchase Agreement"). The Purchase Agreement affords the Issuer sole discretion to place up to 14,970,060 shares of Common Stock or as few as 9,730,539 shares of Common Stock to the Reporting Person. The shares are issuable at price of $3.34 per share of Common Stock in accordance with the terms of the Purchase Agreement.

F2: The closing of the Purchase Agreement is anticipated to occur in approximately two weeks' time.